Advertisement

Läsionen der Leber

  • Harun Badakhshi
Chapter
  • 351 Downloads

Zusammenfassung

Für die Läsionen der Leber ist in differenzialtherapeutischer Hinsicht in den vergangenen Jahren ein relativer Anstieg an Publikationen zu verzeichnen. Unter diesen finden sich ausreichende Hinweise über die Optionen und Möglichkeiten der hochpräzisen Radiotherapie. Solide maligne Tumoren mit Oligometastasen in der Leber scheinen eine andere Biologie aufzuweisen als primär polymetastasierte Malignome. Die limitierte metastatische Kapazität mancher Malignome bietet, vor allem bei der Leber, eine gute Option des kurativen Therapieversuchs. Die Kombination von hochpräziser Radiotherapie mit molekular selektiv wirkenden Medikamenten bedeutet einen deutlichen Schritt in die Richtung wirklich personalisierter Therapie. Im klinischen Alltag kann sie eine Erweiterung des onkologischen Therapiearsenals darstellen. Die primären Malignome der Leber haben dagegen eine schlechte Prognose. Die therapeutischen Optionen sind eher limitiert. Die Applikation der hochpräzisen Radiotherapietechnologien bedeutet hier einen klaren Fortschritt.

Literatur

  1. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM (1984) Resection of hepatic metastases from colorectal cancer. Archives of surgery 119(6):647–651CrossRefPubMedGoogle Scholar
  2. Aitken KL, Hawkins MA (2015) Stereotactic body radiotherapy for liver metastases. Clinical oncology 27(5):307–315CrossRefPubMedGoogle Scholar
  3. Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer research 29(8):3381–3384PubMedGoogle Scholar
  4. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117(17):4060–4069CrossRefPubMedGoogle Scholar
  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of surgery 230(3):309–318; discussion 18–21CrossRefPubMedPubMedCentralGoogle Scholar
  6. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM (1996) Treatment of colorectal cancer: hepatic metastasis. Seminars in surgical oncology 12(4):219–252CrossRefPubMedGoogle Scholar
  7. Goodman BD, Mannina EM, Althouse SK, Maluccio MA, Cardenes HR (2015) Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Practical radiation oncology 6(2):86–95CrossRefPubMedGoogle Scholar
  8. Herfarth KK, Debus J, Lohr F, Bahner ML, Fritz P, Hoss A et al (2000) Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. International journal of radiation oncology, biology, physics 46(2):329–335CrossRefPubMedGoogle Scholar
  9. Herfarth KK, Debus J, Wannenmacher M (2004) Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Frontiers of radiation therapy and oncology 38:100–105CrossRefPubMedGoogle Scholar
  10. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. International journal of radiation oncology, biology, physics 67(3):793–798CrossRefPubMedGoogle Scholar
  11. Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y et al (2015) Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatology research: the official journal of the Japan Society of Hepatology 45(4):378–386CrossRefGoogle Scholar
  12. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, Maluccio M et al (2015) Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical radiation oncology 5(5):e443–449CrossRefPubMedGoogle Scholar
  13. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27(10):1585–1589CrossRefGoogle Scholar
  14. Meng M, Wang H, Zeng X, Zhao L, Yuan Z, Wang P et al (2015) Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma. Drug discoveries & therapeutics 9(5):372–379CrossRefGoogle Scholar
  15. Petrelli F, Coinu A, Zaniboni A, Pietrantonio F, Barni S (2016) Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. Reviews on recent clinical trials 11(1):56–62CrossRefPubMedGoogle Scholar
  16. Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. The American journal of roentgenology, radium therapy, and nuclear medicine 71(5):826–834PubMedGoogle Scholar
  17. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Annals of surgical oncology 18(4):1081–1087CrossRefPubMedGoogle Scholar
  18. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27(10):1572–1578CrossRefGoogle Scholar
  19. Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y et al (2015) Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. Hepatology research: the official journal of the Japan Society of Hepatology 45(5):540–547CrossRefGoogle Scholar
  20. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE (2005) A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. International journal of radiation oncology, biology, physics 62(5):1371–1378CrossRefPubMedGoogle Scholar
  21. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. International journal of radiation oncology, biology, physics 86(2):336–342CrossRefPubMedGoogle Scholar
  22. Scorsetti M, Clerici E, Comito T (2014) Stereotactic body radiation therapy for liver metastases. Journal of gastrointestinal oncology 5(3):190–197PubMedPubMedCentralGoogle Scholar
  23. Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C et al (2015) The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). Journal of cancer research and clinical oncology 141(7):1301–1309CrossRefPubMedGoogle Scholar
  24. Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E et al (2015) Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. Journal of cancer research and clinical oncology 141(3):543–553CrossRefPubMedGoogle Scholar
  25. Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al] 190(10):872–881CrossRefGoogle Scholar
  26. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Annals of surgery 199(5):502–508PubMedGoogle Scholar
  27. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K et al (2006) Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta oncologica 45(7):838–847CrossRefPubMedGoogle Scholar
  28. Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T et al (2015) Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. Journal of radiation research 56(3):561–567CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Harun Badakhshi
    • 1
  1. 1.Direktor der Klinik für integrative RadioonkologieKlinikum Ernst von Bergmann, akademisches Krankenhaus der CharitéPotsdamDeutschland

Personalised recommendations